Table 3 |
||||
|
Treatment terminations for adverse events in original and re-employed methotrexate therapies |
||||
| Re-employed course |
Total |
|||
|
|
||||
| No adverse event |
Adverse event |
|||
|
|
||||
| Original Course |
No adverse event |
45 (13.7 ± 5.2/18.4 ± 5.3) |
10 (10.5 ± 3.8/13.5 ± 4.4) |
55 (13.1 ± 5.1/17.5 ± 5.5) |
| Adverse event |
16 (10.2 ± 3.6/14.8 ± 6.3) |
8 (8.6 ± 1.3/9.1 ± 2.9) |
24 (9.7 ± 3.1/12.9 ± 6.2) |
|
| Total |
61 (12.8 ± 5.0/17.5 ± 5.7) |
18 (9.7 ± 3.2/11.5 ± 4.4) |
79 (12.1 ± 4.8/16.1 ± 6.0) |
|
|
|
||||
|
The numbers in parentheses are the doses in the original methotrexate/re-employed methotrexate courses (mean ± standard deviation) in mg/week). The percentage of patients who were concordant for the presence or absence of adverse events was 66.6% (P = 0.327, by McNemar test). |
||||
|
Kapral et al. Arthritis Research & Therapy 2006 8:R46 doi:10.1186/ar1902 |
||||
